永安药业(002365) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥296,215,023.50, a decrease of 28.32% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2022 was ¥45,059,208.86, an increase of 28.07% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥35,453,786.44, up 10.57% from the previous year[5]. - Basic earnings per share for Q3 2022 were ¥0.15, reflecting a 15.38% increase compared to the same period last year[5]. - The company reported a significant increase in net profit for the year-to-date period, up 96.16% to ¥161,651,432.87[5]. - Net profit rose by 72.61% to ¥154,787,504.15, driven by an increase in total profit[9]. - Total profit increased by 80.49% to ¥178,007,501.11, reflecting strong operational performance[9]. - Net profit for the period was CNY 154,787,504.15, an increase of 72.8% compared to CNY 89,676,826.97 in the previous period[24]. - Earnings per share (EPS) for the period was CNY 0.55, up from CNY 0.29 in the previous period[25]. Cash Flow - The operating cash flow net amount for the year-to-date period reached ¥269,339,615.97, a significant increase of 1,936.77%[5]. - Cash flow from operating activities surged by 1936.77% to ¥269,339,615.97, mainly due to increased sales revenue[9]. - The net cash flow from operating activities for the current period is ¥269,339,615.97, a significant increase from ¥13,223,888.88 in the previous period, reflecting a strong operational performance[26]. - Cash inflow from operating activities totaled ¥1,381,813,769.42, compared to ¥1,002,332,853.61 in the previous period, indicating a year-over-year growth of approximately 37.8%[26]. - The cash outflow from operating activities was ¥1,112,474,153.45, up from ¥989,108,964.73, resulting in a net cash flow from operating activities increase of over 1,900%[26]. - The net cash flow from investing activities was -¥250,340,254.71, a decline from a positive cash flow of ¥128,632,637.28 in the previous period, indicating increased investment expenditures[27]. - Total cash inflow from financing activities was ¥31,000,000.00, compared to ¥24,800,000.00 in the previous period, showing a growth of approximately 25%[27]. - The net cash flow from financing activities decreased to -¥10,492,232.43 from -¥140,529,002.14, indicating improved cash management in financing[27]. - The cash and cash equivalents at the end of the period amounted to ¥108,963,400.62, slightly down from ¥111,369,310.81 in the previous period[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,364,072,956.00, representing a 3.42% increase from the end of the previous year[5]. - Total assets increased to CNY 2,364,072,956.00, compared to CNY 2,285,925,658.35 in the previous period[22]. - Total liabilities decreased to CNY 240,098,614.08 from CNY 328,946,760.67 in the previous period, a reduction of 27%[22]. - The company's equity attributable to shareholders increased to CNY 2,038,260,282.58, up from CNY 1,865,919,415.64 in the previous period[22]. - Shareholders' equity attributable to the parent company increased by 9.24% to ¥2,038,260,282.58 compared to the end of the previous year[5]. Operational Highlights - The weighted average return on equity for the year-to-date period was 8.28%, an increase of 3.71% compared to the previous year[5]. - Trading financial assets increased by 41.08% to ¥640,532,225.73 due to an increase in wealth management scale[9]. - Accounts receivable decreased by 54.03% to ¥42,281,085.77 primarily due to the maturity of endorsed notes[9]. - Other income rose by 76.44% to ¥5,275,193.12, mainly from increased government subsidies received by subsidiaries[9]. - Research and development expenses were CNY 32,891,798.69, down from CNY 39,209,392.77 in the previous period, indicating a focus on cost management[23]. Investments and Expansion - The company plans to expand its production capacity for taurine food additives by 40,000 tons annually, with an investment of RMB 250 million[13]. - The company provided a guarantee for its subsidiary Hubei Ling'an Technology Co., Ltd. to apply for bank credit of up to RMB 30 million[13]. - A framework agreement was signed with Zhejiang Shuangzi Intelligent Equipment Co., Ltd. for equipment manufacturing and system integration, with a total transaction amount not exceeding RMB 50 million[14]. - Hubei Ling'an Technology Co., Ltd. established a new subsidiary, Hubei Ze'an New Materials Co., Ltd., with a registered capital of RMB 1 million, holding a 50.1% stake[15]. - Hubei Ling'an Technology Co., Ltd. also set up a joint venture, Hubei Ling'an Chemical Co., Ltd., with a registered capital of RMB 1 million, holding a 49% stake[15].